The U.S. Food and Drug Administration needs more time to review Abbott Laboratories' experimental cholesterol drug TriLipix, the company said Wednesday evening. Though Wall Street analysts were expecting Abbott to win approval of TriLipix by the end of this month, the North Chicago-based company has said it expects the drug to be approved in the fourth quarter, a forecast that has not changed, company officials said Wednesday.
